Q1 2027 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Jagsonpal Pharmaceuticals Ltd (BOM:507789) reported a 9% revenue growth in Q1 FY27, with operating EBITDA up 21% and net profit up 22%, indicating strong operational performance.
- The acquisition of a controlling stake in Equitas Healthcare provides immediate entry into the hospital segment, expanding network by 49 institutional medical representatives and access to over 1,000 hospitals.
- The company completed a Rs. 40 crore share buyback at a 40% premium, which was oversubscribed 3.67 times, and recouped almost 50% of the payout within the quarter, reflecting strong cash generation.
- Gross margins improved to 65% plus, with EBITDA margins expanding by 240 bps and PAT margins by 176 bps, showcasing enhanced profitability.
- The company's power brand portfolio grew 19% versus the market growth of 16%, with five brands ranking number one in their respective molecules and 14 brands among the top five.
- The company has a strong balance sheet with closing cash of Rs. 170 crores, enabling continued investment in organic and inorganic growth opportunities.
- The company's reported revenue growth of 9% is significantly lower than the external Pharma AI data growth of 18.9%, indicating a variance between primary and secondary sales that management is still investigating.
- Equitas Healthcare has a low gross margin profile compared to the branded prescription business, which may pressure overall profitability as it integrates.
- The hospital business (Equitas) has a longer working capital cycle, which could impact the company's overall cash conversion efficiency.
- The company faces concentration risk with the Maintain brand, which is a significant contributor to growth, and management acknowledged the need to diversify growth across other brands.
- The integration of Equitas is expected to take time, with meaningful contributions only expected from the second year onwards, and the company has set an aggressive EBITDA target of Rs. 10 crores by year two, which may be challenging to achieve.
- The company's growth is partly dependent on reducing attrition and improving field force productivity, which are ongoing challenges in the pharmaceutical industry.
Ladies and Gentlemen, Good day and welcome to Jackson Park Pharmaceuticals Limited Q1 FY27's Earnings Conference Call. (Operator Instructions)
I now hand over the call to Ms. Soumya Chajjais From Go India Advisors. Thank you and over to you ma'am.
Good day everyone and Welcome to Q1 FY27 Earnings call of Jagsonpal Pharmaceuticals Ltd. We have on call with us Mr. Manish Gupta, Managing Director, Mr. Amrut Medhekar, Chief Operating Officer and Mr. Nirav Vora , Chief Financial Officer. Please be reminded that discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risk pertaining to the business. I now request the management. To take the shoes the same and provide some more insight on the quarter and we have gone by. For that, we'll open the floor to Q&A. Thank you and over to you, sir.
Thank you, Soumya, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
